SIBO: Why Your Bloating and Gut Symptoms Keep Coming Back

Jessica Meyers, PA-C

You have tried cutting out gluten. You have eliminated dairy. You have taken probiotics, followed elimination diets, and kept a food journal for months. And yet the bloating returns. The cramping returns. The fatigue and brain fog that no one seems to be able to explain return.

The problem may not be what you are eating. It may be where your bacteria are living.

Small intestinal bacterial overgrowth, or SIBO, is one of the most underdiagnosed drivers of chronic digestive symptoms. It’s also one of the most frequently mistreated. Understanding what it actually is, why it develops, and why it tends to come back is the starting point for treating it effectively.

What Is SIBO and Why Does It Happen?

The small intestine is supposed to be relatively low in bacteria. Most of the gut's microbial population belongs in the large intestine, further downstream. When bacteria migrate into or proliferate within the small intestine in abnormal quantities, they begin fermenting food that should have been absorbed before reaching them. That fermentation produces gas, triggers inflammation, and disrupts nutrient absorption. It generates a wide range of symptoms that often get misattributed to food sensitivities or irritable bowel syndrome.

SIBO is almost always the downstream consequence of something else: impaired gut motility, reduced stomach acid, anatomical changes from prior surgery, immune dysfunction, or medications that slow the gut's natural clearance mechanisms. The American Gastroenterological Association notes that in the vast majority of cases, SIBO results from an underlying condition that promotes bacterial stasis in the small bowel. [1] Common contributors include long-term use of proton pump inhibitors, opioid medications, GLP-1 receptor agonists like semaglutide, hypothyroidism, chronic stress, and advancing age. [2,3]

The bottom line: treating SIBO without addressing what caused it is why so many people relapse.

Your Symptoms Have an Explanation

SIBO does not produce one uniform symptom picture. The specific gas profile produced by overgrown bacteria determines which symptoms dominate. There are three recognized subtypes, each with a distinct pattern.

Bloating and gas. Excess bacteria fermenting carbohydrates in the small intestine produce hydrogen or methane gas that has nowhere productive to go. Distension, flatulence, and a visibly distended abdomen after meals are hallmark complaints across all SIBO subtypes. [4]

Diarrhea. Hydrogen-predominant SIBO, the most common subtype, is strongly associated with loose stools, urgency, and postprandial cramping. A 2025 real-world study of over 3,000 patients confirmed that higher hydrogen levels correlate directly with more severe diarrhea. [4]

Constipation. Intestinal methanogen overgrowth, or IMO, is driven not by bacteria but by archaea, microorganisms that produce methane gas. Methane directly slows intestinal transit, making constipation and bloating with fatty or floating stools the defining symptoms of this subtype. [5,6]

Pain and urgency. A third subtype, intestinal sulfide overproduction, produces hydrogen sulfide gas and is associated with the most severe overall symptom burden- particularly abdominal pain, urgency, and diarrhea. [4]

Fatigue and brain fog. Systemic symptoms including fatigue, poor concentration, and low energy are frequently reported by SIBO patients and are thought to reflect the inflammatory burden of chronic bacterial overgrowth and nutrient malabsorption. [7]

Nutrient deficiencies. In more established cases, SIBO bacteria consume vitamin B12 before the body can absorb it, and disrupt bile acid function in ways that impair absorption of fat-soluble vitamins A, D, E, and K. Anemia, bone density loss, and immune dysfunction can follow. [5,7]

Why Your Body Has Trouble Clearing It

The gut has a built-in mechanism for keeping the small intestine clean. During fasting periods between meals, a wave of muscular contractions called the migrating motor complex, or MMC, sweeps bacteria distally through the small bowel. It functions as the gut's natural housekeeping cycle. When it works properly, bacteria do not get the opportunity to settle and proliferate in the small intestine. [8]

The MMC only activates during fasting. Every time you eat or snack, it resets. This means that for people who graze throughout the day, the housekeeper never runs its full cycle. Add in a medication that slows gut motility, or a history of elevated stress, and the MMC becomes increasingly impaired. Bacteria accumulate. SIBO develops.

Even with treatment, recurrence rates are high. Research shows that 12.6% of patients test positive again within 3 months of completing antibiotics, 27.5% within 6 months, and 43.7% within 9 months. [2] The antibiotic eradicated the overgrowth. It did not fix the underlying conditions that allowed it to develop.

Why SIBO Is So Hard to Fully Eradicate

Two factors make SIBO particularly resistant to standard treatment: biofilm formation and an unchanged gut environment.

Bacteria in the small intestine do not simply float freely in the lumen. Over time, they organize into structured communities embedded in a protective matrix called a biofilm. This matrix physically blocks antibiotics from reaching the bacteria inside, slows bacterial metabolism to a state where antibiotics are less effective, and enables bacteria to transfer resistance genes to one another. Organisms within biofilms can be up to 1,000 times more resistant to antibiotics than free-floating bacteria. [9,10] This is why a single antibiotic course produces breath test normalization in only 20 to 75 percent of patients, and why symptom recurrence is so common even after a technically successful course. [2,11]

Certain agents have shown promise in disrupting biofilm architecture. N-acetylcysteine, or NAC, destabilizes the structural matrix of biofilms and has been shown to improve antibiotic penetration into deeper biofilm layers when used as an adjunct to treatment. [12] Bismuth compounds carry direct antimicrobial properties and have been used empirically alongside rifaximin and neomycin in refractory cases, though robust clinical trials specific to SIBO remain limited. [13] Prokinetic agents restore MMC function and represent an indirect anti-biofilm strategy. One retrospective study found that patients on prokinetics had a dramatically lower rate of positive breath tests than those without them. [3]

What to Do With This Information

If your gut symptoms follow a predictable pattern; bloating that never fully resolves, constipation alternating with loose stools, fatigue after meals, recurring symptoms after periods of dietary restriction- SIBO warrants serious consideration.

Effective treatment addresses four things simultaneously: eradication of the overgrowth, disruption of biofilm where present, restoration of the gut's natural clearance mechanisms, and correction of the underlying conditions that allowed SIBO to develop. That last piece is where long-term success is won or lost.

Behavioral changes that support MMC function matter enormously. Allowing four to five hours between meals rather than grazing throughout the day gives the gut time to run its housekeeping cycle. A minimum twelve-hour overnight fast extends that window further. Moderate physical activity, alcohol reduction, structured sleep, and stress management all support the motility and barrier function that keep SIBO from returning. 

Nutrient support matters as well. DAO enzyme function, relevant when SIBO is contributing to histamine intolerance, depends on adequate vitamin B6, copper, and zinc. Vitamin D, B12, and iron should be monitored and repleted in patients with active or prior SIBO given the malabsorption risk.

Getting to the root of this requires a complete clinical picture: comprehensive gut assessment, a full medication review, motility evaluation, and targeted lab work. A positive breath test is the beginning of the workup, not the end of it.

If you suspect SIBO or have been treated for it more than once without lasting relief, become a patient through the link below. Our Fullscript dispensary carries vetted formulations for gut barrier support, biofilm disruption, prokinetic nutrients, and B12 and fat-soluble vitamin repletion. When shopping through our Fullscript dispensary, you save 15% off every order automatically. When you become a patient, you’ll save even more- 30% off every supplement, every order! 

References

1. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020.

2. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. The American Journal of Gastroenterology. 2020.

3. Damianos JA, Wang XJ, Camilleri M. Mechanisms and Pathophysiology Leading to Development of Small Intestinal Microbial Dysbiosis. The Lancet Gastroenterology & Hepatology. 2026.

4. Pimentel M, Leite G, Joo L, et al. Real-World Study of Three-Gas Breath Testing Nationwide and the Association With Symptoms. Journal of Clinical Gastroenterology. 2025.

5. Madigan KE, Bundy R, Weinberg RB. Distinctive Clinical Correlates of Small Intestinal Bacterial Overgrowth With Methanogens. Clinical Gastroenterology and Hepatology. 2022.

6. Barlow GM, Pimentel M. Modern Concepts of Small Intestinal Bacterial Overgrowth. Current Opinion in Gastroenterology. 2025.

7. Efremova I, Maslennikov R, Poluektova E, et al. Epidemiology of Small Intestinal Bacterial Overgrowth. World Journal of Gastroenterology. 2023.

8. Deloose E, Tack J. Redefining the Functional Roles of the Gastrointestinal Migrating Motor Complex and Motilin in Small Bacterial Overgrowth and Hunger Signaling. American Journal of Physiology: Gastrointestinal and Liver Physiology. 2016.

9. Hall CW, Mah TF. Molecular Mechanisms of Biofilm-Based Antibiotic Resistance and Tolerance in Pathogenic Bacteria. FEMS Microbiology Reviews. 2017.

10. Bano S, Hassan N, Rafiq M, et al. Biofilms as Battlefield Armor for Bacteria Against Antibiotics: Challenges and Combating Strategies. Microorganisms. 2023.

11. Khurmatullina AR, Andreev DN, Kucheryavyy YA, et al. The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2025.

12. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-Acetylcysteine as Powerful Molecule to Destroy Bacterial Biofilms: A Systematic Review. European Review for Medical and Pharmacological Sciences. 2014.

13. Gorbach SL. Bismuth Therapy in Gastrointestinal Diseases. Gastroenterology. 1990.